LDN193189 (Tetrahydrochloride) [2310134-98-4]
Cat# HY-12071A-10mg
Size : 10mg
Brand : MedChemExpress
Please arrange your schedule properly.
- United States
- Canada
- United Kingdom
- Australia
- Germany
- France
- Japan
- Korea South
- Switzerland
- Algeria
- Argentina
- Austria
- Belgium
- Brazil
- Chile
- Croatia
- Czech Republic
- Denmark
- Finland
- Hong Kong, China
- Hungary
- India
- Iraq
- Ireland
- Israel
- Italy
- Lebanon
- Luxembourg
- Malaysia
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Pakistan
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Russia
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Taiwan, China
- Thailand
- Tunisia
- Turkey
- Ukraine
- Macao, China
- Other Countries
LDN193189 Tetrahydrochloride (Synonyms: DM-3189 Tetrahydrochloride)
- Cat. No.: HY-12071A Purity: 99.86%
- COA Handling Instructions
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM).
For research use only. We do not sell to patients.
LDN193189 Tetrahydrochloride Chemical Structure
CAS No. : 2310134-98-4
Size | Price | Stock | Quantity |
---|---|---|---|
Solid + Solvent | |||
10 mM * 1 mL
in Water
ready for reconstitution
|
USD 102 | In-stock | |
Solution | |||
10 mM * 1 mL in Water | USD 102 | In-stock | |
Solid | |||
5 mg | USD 84 | In-stock | |
10 mg | USD 108 | In-stock | |
50 mg | USD 288 | In-stock | |
100 mg | Get quote | ||
200 mg | Get quote |
* Please select Quantity before adding items.
This product is a controlled substance and not for sale in your territory.
Customer Review
Based on 48 publication(s) in Google Scholar
Other Forms of LDN193189 Tetrahydrochloride:
- LDN193189 In-stock
- LDN-193189 dihydrochloride In-stock
- •Nature. 2022 May;605(7909):325-331. [Abstract]
- •Eur Respir J. 2021 Dec 2;2100327. [Abstract]
- •Adv Sci (Weinh). 2024 Jan 18:e2308072. [Abstract]
- •Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4. [Abstract]
- •J Hazard Mater. 2023 Nov 19, 133028.
- •Biomaterials. 2020 May;240:119849. [Abstract]
- •Cell Rep. 2023 Dec 5;42(12):113541. [Abstract]
- •Cancer Lett. 2020 Jan 28;469:390-398. [Abstract]
- •Cell Rep. 2017 Aug 29;20(9):2227-2237. [Abstract]
- •Cell Rep. 2017 Aug 29;20(9):2227-2237. [Abstract]
- •EMBO Rep. 2023 Jul 26;e56454. [Abstract]
- •Stem Cell Res Ther. 2023 Jan 5;14(1):1. [Abstract]
- •Stem Cell Res Ther. 2022 Sep 2;13(1):436. [Abstract]
- •Stem Cell Res Ther. 2022 Aug 19;13(1):424. [Abstract]
- •Stem Cell Res Ther. 2021 Jun 11;12(1):345. [Abstract]
- •Diabetes. 2020 Apr;69(4):634-646. [Abstract]
- •Pigment Cell Melanoma Res. 2023 Aug 9. [Abstract]
- •Cancer Metab. 2023 Jul 13;11(1):9. [Abstract]
- •Stem Cells. 2023 Apr 8;sxad028. [Abstract]
- •iScience. 2022 Dec 26;26(1):105898. [Abstract]
- •Stem Cells Int. 22 Dec 2022.
- •Int J Mol Sci. 2022, 23(23), 14831.
- •Mar Drugs. 2022 Nov 14;20(11):715. [Abstract]
- •Sci Rep. 2022 Mar 18;12(1):4740. [Abstract]
- •Sci Rep. 2022 Mar 25;12(1):5221. [Abstract]
- •Stem Cells Int. 2022 Apr 28;2022:1560943. [Abstract]
- •Front Cell Dev Biol. 13 May 2021.
- •Front Mol Biosci. 2021; 8: 663987.
- •Front Mol Biosci. 2021 Apr 26;8:663987. [Abstract]
- •Transl Oncol. 2019 Dec 19;13(2):125-134 [Abstract]
- •iScience. 2019 Sep 27;19:1248-1259. [Abstract]
- •Biochim Biophys Acta Gen Subj. 29 October 2021, 130046.
- •Prostate. 2021 Sep 23. [Abstract]
- •Exp Ther Med. 2019 Apr;17(4):2648-2656. [Abstract]
- •Cardiovasc Toxicol. 2019 Jun;19(3):264-275. [Abstract]
- •Int J Ophthalmol. 2022 May 18;15(5):711-720. [Abstract]
- •bioRxiv. 2024 Mar 13.
- •bioRxiv. 2024 Mar 25.
- •Research Square Preprint. 2023 May 17.
- •Patent. US20210346386A1.
- •Research Square Preprint. 2021 Sep.
- •Oxid Med Cell Longev. 2020 Jun 8;2020:4175613. [Abstract]
- •Curr Protoc Cell Biol. 2018 Dec;81(1):e62. [Abstract]
- •Patent. US20180263995A1.
- •J Recept Signal Transduct Res. 2017 Oct;37(5):515-521. [Abstract]
- •Harvard Medical School LINCS LIBRARY
-
LDN193189 Tetrahydrochloride purchased from MedChemExpress. Usage Cited in: Oxid Med Cell Longev. 2020 Jun 8;2020:4175613. [Abstract]
- Western blot and grey analysis of CYP11a1, CYP19a1, BCL2, CALR, CHOP, caspase3, caspase12, PERK, and GRP78. qRT-PCR analyzed ATF4, caspase3, and GRP78 mRNAs. The relieving function of BMP4 on ER stress is diminished after blockade of BMP receptor I (BMPRI) with DM-3189.
-
LDN193189 Tetrahydrochloride purchased from MedChemExpress. Usage Cited in: Cardiovasc Toxicol. 2019 Jun;19(3):264-275. [Abstract]
- H9c2 cells are treated as following: control, DOX, DOX + rhBMP (Bmpr1a agonist) and DOX + LDN193189 (Bmpr1a inhibitor). Cells with red fluorescence indicate favorable MMP while green fluorescence indicates damage.
View All TGF-β Receptor Isoform Specific Products:
Biological Activity
Protocol
Purity & Documentation
References
Customer Review
Description | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||
In Vitro |
LDN193189 inhibits BMP4-mediated Smad1, Smad5 and Smad8 activation with great potency (IC50=5 nM) while retaining 200-fold selectivity for BMP signaling versus TGF-β signaling (IC50 for TGF-β ≥1,000 nM)[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
In Vivo |
LDN193189 (Tetrahydrochloride) (i.p.;3 mg/kg;twice a day) shows the growth rates between the control vehicle- and LDN193189-treated mice are not significantly different after the first 5 weeks, but differences in the growth rates are detected after 6 and 7 weeks post-treatment[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
Molecular Weight |
552.33 |
||||||||||||
Formula |
C25H26Cl4N6 |
||||||||||||
CAS No. | |||||||||||||
Appearance |
Solid |
||||||||||||
Color |
Light yellow to yellow |
||||||||||||
SMILES |
C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16.Cl.Cl.Cl.Cl |
||||||||||||
Shipping | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Storage |
4°C, sealed storage, away from moisture *In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture) |
||||||||||||
Solvent & Solubility |
In Vitro:
H2O : 33.33 mg/mL (60.34 mM; Need ultrasonic) DMSO : 4.17 mg/mL (7.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration:
mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
|
||||||||||||
Purity & Documentation |
Purity: 99.86% |
||||||||||||
References |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO / H2O | 1 mM | 1.8105 mL | 9.0526 mL | 18.1051 mL | 45.2628 mL |
5 mM | 0.3621 mL | 1.8105 mL | 3.6210 mL | 9.0526 mL | |
H2O | 10 mM | 0.1811 mL | 0.9053 mL | 1.8105 mL | 4.5263 mL |
15 mM | 0.1207 mL | 0.6035 mL | 1.2070 mL | 3.0175 mL | |
20 mM | 0.0905 mL | 0.4526 mL | 0.9053 mL | 2.2631 mL | |
25 mM | 0.0724 mL | 0.3621 mL | 0.7242 mL | 1.8105 mL | |
30 mM | 0.0604 mL | 0.3018 mL | 0.6035 mL | 1.5088 mL | |
40 mM | 0.0453 mL | 0.2263 mL | 0.4526 mL | 1.1316 mL | |
50 mM | 0.0362 mL | 0.1811 mL | 0.3621 mL | 0.9053 mL | |
60 mM | 0.0302 mL | 0.1509 mL | 0.3018 mL | 0.7544 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
LDN193189 Tetrahydrochloride Related Classifications
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
LDN193189 Tetrahydrochloride2310134-98-4DM-3189 TetrahydrochlorideOrganoidTGF-β ReceptorTransforming growth factor beta receptorsInhibitorinhibitorinhibit
Your Recently Viewed Products:
Inquiry Online
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Product Name:
- LDN193189 Tetrahydrochloride
- Cat. No.:
- HY-12071A
- Quantity:
- MCE Japan Authorized Agent: